Updates on First-line and Subsequent Treatment Options for Advanced Endometrial Cancer

home / insights / updates-on-first-line-and-subsequent-treatment-options-for-advanced-endometrial-cancer

This OncLive Insights features a medical oncologist and gynecologic oncologist who share their thoughts on the selection of first-line and subsequent therapy in advanced endometrial cancer. They discuss treatment strategies and novel therapeutics that may improve health outcomes in patients with the disease.

Experts on endometrial cancer

EP. 1: Endometrial Cancer: A Global Problem

Vicky Makker, MD;Ramez N. Eskander, MD
March 15th 2022

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Expert on endometrial cancer

EP. 2: Molecular Testing in Endometrial Cancer

Vicky Makker, MD;Ramez N. Eskander, MD
March 15th 2022

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Expert on endometrial cancer

EP. 3: First-line Treatment Options for Advanced Endometrial Cancer

Vicky Makker, MD;Ramez N. Eskander, MD
March 22nd 2022

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

Experts on endometrial cancer

EP. 4: The KEYNOTE-775 Trial: Efficacy of Combination Lenvatinib/Pembrolizumab in Endometrial Cancer

Vicky Makker, MD;Ramez N. Eskander, MD
March 22nd 2022

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

Expert on endometrial cancer

EP. 5: Treatment Modification Rates for Combination Lenvatinib/Pembrolizumab

Vicky Makker, MD;Ramez N. Eskander, MD
March 29th 2022

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

Expert on endometrial cancer

EP. 6: Management of Adverse Events After Combination Lenvatinib/Pembrolizumab

Vicky Makker, MD;Ramez N. Eskander, MD
March 29th 2022

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Experts on endometrial cancer

EP. 7: Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

Vicky Makker, MD;Ramez N. Eskander, MD
April 5th 2022

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.